Sana's Cash Decreases to $138.4M as of 2025
Cash, cash equivalents, and marketable securities as of December 31, 2025 were $138.4M compared to $152.5M as of December 31, 2024. The decrease of $14.1M was primarily driven by cash used in operations of $143.8M, partially offset by net proceeds from equity financings of $126.4M, proceeds from stock option exercises and Sana's employee stock purchase plan of $2.7M, and other cash inflows. "Meaningful scientific and operational progress in 2025 has positioned us well to generate human proof-of-concept data over the next 12-18 months for SC451 in type 1 diabetes and SG293 in blood cancers," said Steve Harr, Sana's president and CEO. "Clinical data for UP421, a study which is now out beyond a year, provide the first known example of transplanting an allogeneic cell therapy for the treatment of type 1 diabetes without any immunosuppression. These results, when combined with progress in the field of transplanting pancreatic islets, make us optimistic that SC451, which incorporates the same hypoimmune gene edits into a more scalable manufacturing platform, can lead to a functional cure for people with type 1 diabetes, meaning normal blood glucose, no more insulin injections, and no immunosuppression. Moving to the fusogen platform, we made improvements to our in vivo CAR T platform with our next-generation SG293 candidate, offering the potential for a simple, one-time, off-the-shelf treatment without the use of conditioning chemotherapy for the treatment of B cell cancers and B cell-mediated autoimmune diseases. We look forward to beginning clinical trials for both of these therapies this year. With two powerful platforms advancing in parallel, we look to drive meaningful clinical benefit for patients."
Trade with 70% Backtested Accuracy
Analyst Views on SANA
About SANA
About the author
Sana Biotechnology Reports Q4 Results with Expanded Losses
- Financial Overview: Sana Biotechnology reported an adjusted net loss of $44.74 million for Q4, or $0.16 per share, a decrease from $54.79 million and $0.23 per share last year, indicating efforts in cost management; however, the overall net loss expanded to $58.83 million, reflecting ongoing financial challenges.
- R&D Progress and Milestones: The company aims to generate human proof-of-concept data for SC451 and SG293 within the next 12-18 months, with SC451 targeting type 1 diabetes and SG293 focusing on blood cancers, suggesting that advancements in these critical therapeutic areas could position Sana competitively in the market.
- Cash Flow and Financing Status: As of Q4 2025, Sana reported a cash position of $138.4 million, with an expected runway into late 2026, ensuring funding for R&D and operations, which enhances investor confidence in its long-term growth prospects.
- Clinical Trials and Regulatory Interactions: Multiple interactions with regulators have bolstered confidence in Sana's manufacturing processes and clinical trial plans, with an IND application for SC451 anticipated as early as 2026, followed by Phase 1 trials, demonstrating the company's proactive approach to advancing its product pipeline.
Sana Biotechnology Reports Q4 Earnings Miss
- Earnings Report Disappointment: Sana Biotechnology's Q4 GAAP EPS of -$0.21 missed expectations by $0.07, indicating ongoing challenges in achieving profitability and raising concerns among investors.
- Deteriorating Cash Position: As of December 31, 2025, the company's cash, cash equivalents, and marketable securities totaled $138.4 million, down from $152.5 million in 2024, primarily due to operational cash outflows of $143.8 million, highlighting financial strain.
- Impact of Financing Activities: Despite high operational costs, Sana secured net proceeds of $126.4 million from equity financings and $2.7 million from stock option exercises and employee stock purchase plans, partially alleviating cash flow pressures and demonstrating some financial resilience.
- Cautious Market Reaction: Given the disappointing financial performance and tight cash flow, the market remains cautious about Sana Biotechnology's outlook, which may affect its stock price performance, prompting investors to monitor future financial improvement efforts.
Sana Biotechnology to Present Business Update at 44th J.P. Morgan Healthcare Conference
- Conference Timing: Sana Biotechnology will webcast its presentation at 9:45 a.m. PT on January 14, 2026, aiming to enhance investor understanding of the company's strategic direction through a comprehensive business overview.
- Executive Participation: CEO Steve Harr will lead the presentation, showcasing the latest research advancements in gene repair and cell replacement, which will further elevate the company's influence in the biotechnology sector.
- Webcast Accessibility: The webcast will be available on Sana's Investor Relations page and will include a replay for 30 days post-conference, ensuring investors can access critical information at their convenience.
- Vision Statement: Sana Biotechnology focuses on transforming patient treatment through engineered cells, emphasizing its innovative capabilities in gene repair and cell replacement, which aims to attract more investor interest in its long-term growth potential.
Sana Biotechnology Achieves Potent Gene Editing in Murine Models Using Fusogen Technology
- Technological Breakthrough: Sana's Fusogen technology has achieved potent gene editing of hematopoietic stem cells in murine models, demonstrating stable editing capabilities in the bone marrow, which could transform treatments for diseases like sickle cell disease and beta thalassemia.
- Enhanced Delivery Efficiency: The use of systemically delivered virus-like particles (VLPs) with this technology avoids off-target delivery to hepatocytes, significantly improving the specificity and efficiency of gene editing while reducing side effects during treatment.
- Clinical Application Prospects: Sana plans to file an IND for SG293 by 2027, targeting B-cell cancers and autoimmune diseases, showcasing the broad application potential of Fusogen technology in treating various conditions.
- Strategic Implications: The findings not only expand the application scope of Fusogen technology but also simplify the supply chain and reduce reliance on high-dose chemotherapy, thereby lowering the risks of infections and secondary cancers for patients.
Sana Biotechnology Achieves Potent Gene Editing in Murine Models Using Fusogen Technology
- Technological Breakthrough: Sana's fusogen technology has achieved effective gene editing of hematopoietic stem cells in murine models, demonstrating potent cell specificity and stability, which could transform treatments for diseases like sickle cell disease and beta thalassemia.
- Clinical Application Potential: This technology can overcome limitations of traditional bone marrow transplants and current ex vivo gene editing methods, such as the need for high doses of conditioning chemotherapy, thereby reducing risks of infections and secondary cancers, enhancing patient treatment experiences.
- Product Development Plans: Sana aims to file an IND for SG293 by 2027, which utilizes fusogen technology to generate CD19-targeted CAR T cells in vivo, targeting B-cell cancers and autoimmune diseases, indicating strong market potential.
- Scientific Validation: Recent research published shows that optimized virus-like particles (VLPs) can achieve effective gene editing in long-term human hematopoietic stem cells, further validating the fusogen technology's application potential across multiple cell types.
Three Genomics Stocks Worth Adding to Your Portfolio
Genomics Overview: Genomics, the study of entire genomes, is gaining traction among pharmaceutical and biotech companies due to advancements in personalized medicine and drug development, distinguishing itself from genetics by focusing on gene interactions and their roles in living systems.
Synthetic Biology and Genome Editing: The field of genomics has led to the rise of synthetic biology and genome-editing technologies like CRISPR/Cas9, which allow for precise DNA modifications to treat genetic diseases, with companies like CRISPR Therapeutics and Intellia Therapeutics at the forefront.
Market Growth Projections: The genomics market is projected to reach $80.17 billion by 2032, while the synthetic biology market is expected to grow at a CAGR of 17.30% from 2025 to 2030, indicating significant investment opportunities in these sectors.
Company Highlights: Notable companies in the genomics space include Editas Medicine, which is developing gene editing therapies, Sana Biotechnology, focusing on cell engineering for diseases like type 1 diabetes, and Pacific Biosciences, known for advanced sequencing technologies, all showing promising stock performance.
Sana Biotechnology Reports Q4 Results with Expanded Losses
- Financial Overview: Sana Biotechnology reported an adjusted net loss of $44.74 million for Q4, or $0.16 per share, a decrease from $54.79 million and $0.23 per share last year, indicating efforts in cost management; however, the overall net loss expanded to $58.83 million, reflecting ongoing financial challenges.
- R&D Progress and Milestones: The company aims to generate human proof-of-concept data for SC451 and SG293 within the next 12-18 months, with SC451 targeting type 1 diabetes and SG293 focusing on blood cancers, suggesting that advancements in these critical therapeutic areas could position Sana competitively in the market.
- Cash Flow and Financing Status: As of Q4 2025, Sana reported a cash position of $138.4 million, with an expected runway into late 2026, ensuring funding for R&D and operations, which enhances investor confidence in its long-term growth prospects.
- Clinical Trials and Regulatory Interactions: Multiple interactions with regulators have bolstered confidence in Sana's manufacturing processes and clinical trial plans, with an IND application for SC451 anticipated as early as 2026, followed by Phase 1 trials, demonstrating the company's proactive approach to advancing its product pipeline.
Sana Biotechnology Reports Q4 Earnings Miss
- Earnings Report Disappointment: Sana Biotechnology's Q4 GAAP EPS of -$0.21 missed expectations by $0.07, indicating ongoing challenges in achieving profitability and raising concerns among investors.
- Deteriorating Cash Position: As of December 31, 2025, the company's cash, cash equivalents, and marketable securities totaled $138.4 million, down from $152.5 million in 2024, primarily due to operational cash outflows of $143.8 million, highlighting financial strain.
- Impact of Financing Activities: Despite high operational costs, Sana secured net proceeds of $126.4 million from equity financings and $2.7 million from stock option exercises and employee stock purchase plans, partially alleviating cash flow pressures and demonstrating some financial resilience.
- Cautious Market Reaction: Given the disappointing financial performance and tight cash flow, the market remains cautious about Sana Biotechnology's outlook, which may affect its stock price performance, prompting investors to monitor future financial improvement efforts.
Sana Biotechnology to Present Business Update at 44th J.P. Morgan Healthcare Conference
- Conference Timing: Sana Biotechnology will webcast its presentation at 9:45 a.m. PT on January 14, 2026, aiming to enhance investor understanding of the company's strategic direction through a comprehensive business overview.
- Executive Participation: CEO Steve Harr will lead the presentation, showcasing the latest research advancements in gene repair and cell replacement, which will further elevate the company's influence in the biotechnology sector.
- Webcast Accessibility: The webcast will be available on Sana's Investor Relations page and will include a replay for 30 days post-conference, ensuring investors can access critical information at their convenience.
- Vision Statement: Sana Biotechnology focuses on transforming patient treatment through engineered cells, emphasizing its innovative capabilities in gene repair and cell replacement, which aims to attract more investor interest in its long-term growth potential.
Sana Biotechnology Achieves Potent Gene Editing in Murine Models Using Fusogen Technology
- Technological Breakthrough: Sana's Fusogen technology has achieved potent gene editing of hematopoietic stem cells in murine models, demonstrating stable editing capabilities in the bone marrow, which could transform treatments for diseases like sickle cell disease and beta thalassemia.
- Enhanced Delivery Efficiency: The use of systemically delivered virus-like particles (VLPs) with this technology avoids off-target delivery to hepatocytes, significantly improving the specificity and efficiency of gene editing while reducing side effects during treatment.
- Clinical Application Prospects: Sana plans to file an IND for SG293 by 2027, targeting B-cell cancers and autoimmune diseases, showcasing the broad application potential of Fusogen technology in treating various conditions.
- Strategic Implications: The findings not only expand the application scope of Fusogen technology but also simplify the supply chain and reduce reliance on high-dose chemotherapy, thereby lowering the risks of infections and secondary cancers for patients.
Sana Biotechnology Achieves Potent Gene Editing in Murine Models Using Fusogen Technology
- Technological Breakthrough: Sana's fusogen technology has achieved effective gene editing of hematopoietic stem cells in murine models, demonstrating potent cell specificity and stability, which could transform treatments for diseases like sickle cell disease and beta thalassemia.
- Clinical Application Potential: This technology can overcome limitations of traditional bone marrow transplants and current ex vivo gene editing methods, such as the need for high doses of conditioning chemotherapy, thereby reducing risks of infections and secondary cancers, enhancing patient treatment experiences.
- Product Development Plans: Sana aims to file an IND for SG293 by 2027, which utilizes fusogen technology to generate CD19-targeted CAR T cells in vivo, targeting B-cell cancers and autoimmune diseases, indicating strong market potential.
- Scientific Validation: Recent research published shows that optimized virus-like particles (VLPs) can achieve effective gene editing in long-term human hematopoietic stem cells, further validating the fusogen technology's application potential across multiple cell types.
Three Genomics Stocks Worth Adding to Your Portfolio
Genomics Overview: Genomics, the study of entire genomes, is gaining traction among pharmaceutical and biotech companies due to advancements in personalized medicine and drug development, distinguishing itself from genetics by focusing on gene interactions and their roles in living systems.
Synthetic Biology and Genome Editing: The field of genomics has led to the rise of synthetic biology and genome-editing technologies like CRISPR/Cas9, which allow for precise DNA modifications to treat genetic diseases, with companies like CRISPR Therapeutics and Intellia Therapeutics at the forefront.
Market Growth Projections: The genomics market is projected to reach $80.17 billion by 2032, while the synthetic biology market is expected to grow at a CAGR of 17.30% from 2025 to 2030, indicating significant investment opportunities in these sectors.
Company Highlights: Notable companies in the genomics space include Editas Medicine, which is developing gene editing therapies, Sana Biotechnology, focusing on cell engineering for diseases like type 1 diabetes, and Pacific Biosciences, known for advanced sequencing technologies, all showing promising stock performance.
